(Q52600736)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

title

Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

Chengwei Zhang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Xiao-Ran Han

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Xiaobao Yang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Biao Jiang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Jing Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Yue Xiong

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Jian Jin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

publication date

27 March 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Medicinal Chemistry

22 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

volume

151

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

304-314

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

22 March 2020

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Proteasome inhibitors: valuable new tools for cell biologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Expression of the ALK tyrosine kinase gene in neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Identification of ALK as a major familial neuroblastoma predisposition gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Oncogenic mutations of ALK kinase in neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Activating mutations in ALK provide a therapeutic target in neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Overall genomic pattern is a predictor of outcome in neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Anaplastic lymphoma kinase and leukocyte tyrosine kinase: functions and genetic interactions in learning, memory and adult neurogenesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Widening Synthesis Bottlenecks: Realization of Ultrafast and Continuous-Flow Synthesis of High-Silica Zeolite SSZ-13 for NOx Removal.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Catalytic in vivo protein knockdown by small-molecule PROTACs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Small-Molecule PROTACS: New Approaches to Protein Degradation

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Induced protein degradation: an emerging drug discovery paradigm

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

ALK: a tyrosine kinase target for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Targeting ALK: Precision Medicine Takes on Drug Resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Structural basis of PROTAC cooperative recognition for selective protein degradation

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29627725

12 December 2020

10.1016/J.EJMECH.2018.03.071

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29627725%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

PubMed publication ID

29627725

1 reference